Abstract：
BACKGROUND: Map-like redness is a newly identified endoscopic risk factor for gastric cancer in patients who received Helicobacter pylori eradication therapy. However, the incidence rate of map-like redness in patients who received eradication, and the risk factors for the development of map-like redness remain unclear. We hence aimed to investigate the incidence rate of map-like redness at 1-year post H. pylori eradication, and evaluated its associations with map-like redness and gastric cancer in relation with gastric condition.
METHODS: Endoscopic severity of gastritis and map-like redness were retrospectively evaluated according to the Kyoto Classification of Gastritis in patients who had undergone endoscopy before and after H. pylori eradication therapy.
RESULTS: The incidence rate of map-like redness for all 328 patients at a mean of 1.2 ± 0.6 years after eradication was 25.3% (95% confidence interval [CI]: 20.7%-30.4%). Patients who developed map-like redness were older, had more severe atrophy and intestinal metaplasia, a higher total score of the Kyoto Classification of Gastritis both before and after eradication, and a higher rate of gastric cancer history than patients who did not have map-like redness. On multivariate analysis, risk of map-like redness was increased in patients with intestinal metaplasia (odds ratio [OR]: 2.794, 95% CI: 1.155-6.757) and taking acid inhibitors (OR: 1.948, 95% CI: 1.070-3.547). Characteristics of H. pylori-positive patients with gastric cancer history were patients who were older (OR: 1.033, 95% CI: 1.001-1.066), taking acid inhibitors (OR: 4.456, 95% CI: 2.340-8.484), and with occurrence of map-like redness after eradication therapy (OR: 2.432, 95% CI: 1.264-4.679).
CONCLUSIONS: Map-like redness is observed in one fourth of patients at 1-year post eradication. Patients who developed map-like redness were found to have severe intestinal metaplasia and taking acid inhibitors, and hence such patients require increased attention at surveillance endoscopy.
METHODS: Endoscopic severity of gastritis and map-like redness were retrospectively evaluated according to the Kyoto Classification of Gastritis in patients who had undergone endoscopy before and after H. pylori eradication therapy.
RESULTS: The incidence rate of map-like redness for all 328 patients at a mean of 1.2 ± 0.6 years after eradication was 25.3% (95% confidence interval [CI]: 20.7%-30.4%). Patients who developed map-like redness were older, had more severe atrophy and intestinal metaplasia, a higher total score of the Kyoto Classification of Gastritis both before and after eradication, and a higher rate of gastric cancer history than patients who did not have map-like redness. On multivariate analysis, risk of map-like redness was increased in patients with intestinal metaplasia (odds ratio [OR]: 2.794, 95% CI: 1.155-6.757) and taking acid inhibitors (OR: 1.948, 95% CI: 1.070-3.547). Characteristics of H. pylori-positive patients with gastric cancer history were patients who were older (OR: 1.033, 95% CI: 1.001-1.066), taking acid inhibitors (OR: 4.456, 95% CI: 2.340-8.484), and with occurrence of map-like redness after eradication therapy (OR: 2.432, 95% CI: 1.264-4.679).
CONCLUSIONS: Map-like redness is observed in one fourth of patients at 1-year post eradication. Patients who developed map-like redness were found to have severe intestinal metaplasia and taking acid inhibitors, and hence such patients require increased attention at surveillance endoscopy.
摘要：
背景：在接受幽门螺杆菌根除治疗的患者中，Map样红肿是一种新发现的胃镜下胃癌危险因素。然而,接受根除的患者中地图样红肿的发生率，地图样发红的危险因素尚不清楚。因此，我们旨在调查幽门螺杆菌根除后1年地图样红肿的发生率，并评估了其与图样发红和胃癌与胃状况的关系。
方法：根据胃镜检查根除幽门螺杆菌治疗前后的胃炎患者的胃镜严重程度和地图样红肿进行回顾性评估。
结果：在根除后平均1.2±0.6年，所有328例患者的地图样红肿发生率为25.3%（95%置信区间[CI]：20.7%-30.4%）。出现地图样发红的患者年龄较大，有更严重的萎缩和肠上皮化生，根除前后胃炎京都分类法总分较高，与没有地图样发红的患者相比，胃癌病史的发生率更高。在多变量分析中，在肠上皮化生(比值比[OR]:2.794,95%CI:1.155~6.757)和服用酸抑制剂(OR:1.948,95%CI:1.070~3.547)的患者中,地图样红肿的风险增加.有胃癌病史的幽门螺杆菌阳性患者的特征是年龄较大的患者（OR：1.033，95％CI：1.001-1.066），服用酸抑制剂（OR：4.456，95%CI：2.340-8.484），根除治疗后出现地图样红肿(OR:2.432,95%CI:1.264-4.679)。
结论：根除后1年，四分之一的患者出现Map样发红。出现地图样发红的患者被发现患有严重的肠上皮化生，并服用酸抑制剂，因此，这类患者在监督内窥镜检查时需要更多的关注。
方法：根据胃镜检查根除幽门螺杆菌治疗前后的胃炎患者的胃镜严重程度和地图样红肿进行回顾性评估。
结果：在根除后平均1.2±0.6年，所有328例患者的地图样红肿发生率为25.3%（95%置信区间[CI]：20.7%-30.4%）。出现地图样发红的患者年龄较大，有更严重的萎缩和肠上皮化生，根除前后胃炎京都分类法总分较高，与没有地图样发红的患者相比，胃癌病史的发生率更高。在多变量分析中，在肠上皮化生(比值比[OR]:2.794,95%CI:1.155~6.757)和服用酸抑制剂(OR:1.948,95%CI:1.070~3.547)的患者中,地图样红肿的风险增加.有胃癌病史的幽门螺杆菌阳性患者的特征是年龄较大的患者（OR：1.033，95％CI：1.001-1.066），服用酸抑制剂（OR：4.456，95%CI：2.340-8.484），根除治疗后出现地图样红肿(OR:2.432,95%CI:1.264-4.679)。
结论：根除后1年，四分之一的患者出现Map样发红。出现地图样发红的患者被发现患有严重的肠上皮化生，并服用酸抑制剂，因此，这类患者在监督内窥镜检查时需要更多的关注。
